No registrations found.
ID
Source
Brief title
Health condition
acute myocardial infarction, scheduled for emergency coronary angioplasty
Sponsors and support
Dr Giuseppe De Luca
Department of Cardiology
ISALA Klinieken
Hospital De Weezenlanden
Zwolle, The Netherlands
Intervention
Outcome measures
Primary outcome
Major adverse cardiac clinical events (death, re-infarction, target vessel revascularization) at 1, 9 and 12 months after treatment.
Secondary outcome
Late lumen loss at 9 months follow-up by quantitative coronary angiography.
Background summary
Title of Study:
Cypher drug-Eluting stent.
A Zwolle AMI Randomized trial
Purpose:
To compare Rapamycin vs Paclitaxel - eluting stent, in patients with acute myocardial infarction.
Study Design:
Single-center, prospective, randomized trial
Study Phase:
Randomized Phase III.
Study Devices:
- Bx VELOCITYTM stent coated with rapamycin (Cypher)
- TaxusTM , stent coated with Paclitaxel.
Diagnosis and criteria for inclusion Patients with acute myocardial infarction, scheduled for emergency coronary angioplasty.
Intended use of the devices to achieve an increased lumen diameter of a (re) stenosis or occlusion in a coronary artery, which allows improved perfusion and performance.
Sample size:
352 patients with acute myocardial infarction.
Statistical methods:
Clinical and angiographic data will be analyzed both according to the principle of intention-to-treat and evaluable group analyses. End-point variables will be presented by means of 95% confidence intervals for the mean difference for quantitative results. An estimate of the relative risk for the treatment groups and the 95% confidence interval of the risk will be provided for 9-month restenosis rate and each of the adverse event parameters. Besides descriptive techniques the actuarial life table method will be used for analyzing occurrence of the adverse events and target vessel revascularization during the one-year follow-up period.
Primary Endpoints: -Late loss at 9 month follow-up by quantitative coronary angiography.
-Major adverse cardiac clinical events (death, re-infarction, target vessel revascularization) at 1, 9 and 12 months after treatment.
Study objective
The study is designed to demonstrate superiority of Cypher stent based on the assumption that at follow-up angiography the late loss is at least 0.15 mm smaller than the mean late loss when the Taxus stent is used.
Study design
N/A
Intervention
Percutane Coronaire Interventie.
Dokter Stolteweg 96
J. Klijn
Dokter Stolteweg 96
Zwolle 8025 AZ
The Netherlands
+31 (0)38 4262997
j.klijn@diagram-zwolle.nl
Dokter Stolteweg 96
J. Klijn
Dokter Stolteweg 96
Zwolle 8025 AZ
The Netherlands
+31 (0)38 4262997
j.klijn@diagram-zwolle.nl
Inclusion criteria
1. Patients with acute myocardial infarction, presenting within 6 hours after symptom-onset, or those presenting between 6 and 24 hours if persisting chest pain associated with clinical evidence of on-going ischemia occurs;
2. Culprit lesion in a native coronary artery, suitable for stenting;
3. Lesion length of < 30 mm, located in a vessel of > 2.5 mm;
4. Able to deliver the stent to target lesion (absence of diffuse disease or excessive proximal vessel tortuosity);
5. Absence of no-reflow or extensive thrombus throughout vessel.
Exclusion criteria
1. Women of child-bearing potential;
2. Severe hepatic or renal disease;
3. Previous participation in the study;
4. Life expectancy of < 1 year;
5. Factors making follow-up difficult;
6. Acute myocardial infarction pre-treated with thrombolysis;
7. Unprotected left main disease or single remaining vessel;
8. Target lesion in a bifurcation with a large side-branch;
9. Known sensitivity to aspirin or coumarin;
10. Unable to provide informed consent.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL79 |
| NTR-old | NTR110 |
| Other | : N/A |
| ISRCTN | ISRCTN90526229 |